Latest News & Features
Refine Search
Americas
The traditional business model for a new drug relies on a substantial period of market exclusivity to recoup extensive research and development costs. 1 May 2011
Americas
US patent reform looks like it may finally be coming. John Pegram and Mark Ellinger explain the proposed changes. 1 May 2011
Americas
The Canadian Federal Court of Appeal recently considered whether ‘invalid selection’ can be an independent ground for invalidating selection patents. Katie Wang looks at the implications. 1 May 2011
Europe
Recent European decisions have provided much to think about for practitioners concerned with DNA sequences. Caroline Pallard and Bart Swinkels investigate. 1 May 2011
Generics
Natural products have been used to relieve a variety of diseases and conditions for millennia. 1 May 2011
Asia
It has taken a long time for India to develop a productive environment for biotechnology. But recent developments look to have put it on the right track. Archana Shanker explains. 1 May 2011
Asia-Pacific
An Australian legislative bill could have grave consequences for the country’s life sciences industry and, potentially, for patients as well. Tania Obranovich explains. 1 May 2011
Big Pharma
There is a general acceptance that European patent law is complicated, particularly in the area of pharmaceutical inventions. Claire Baldock looks at how the EPO approaches these inventions. 1 May 2011
Americas
Homologation (recognition of equivalence) is a useful tool for simplifying administrative processes that are repeated in different countries. Nevertheless, it is not an end in itself. 1 May 2011
Americas
There is a perfect storm brewing in the healthcare industry. Over the past few years, there has been an unprecedented rise in the trade of illicit healthcare products in the secondary market. 1 May 2011